Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 3 4Phase 1 4Phase 2 3Phase 2/3 1

Status

Withdrawn 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Advanced Cancer 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × bempegaldesleukin × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03772288 2023-02-08

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Calithera Biosciences, Inc

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin

NCT03745807 2021-10-04

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
3 enrolled

Advanced Cancer

NCT04955262 2021-07-08

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Nektar Therapeutics

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡